CUTISS
Pioneering bio-engineered skin grafts for severe burns and chronic wounds.
About
CUTISS is a late-stage clinical TechBio company revolutionizing skin surgery with denovoSkin™, a first-in-class personalized tissue therapy for on-demand production of living human skin. This technology is designed for patients requiring skin surgery, from severe burns to reconstructive and aesthetic applications, offering a safe and effective alternative to the standard of care. CUTISS also leverages its scalable, automated production platform for advancements in regenerative medicine, space health research, and industrial bioengineered tissue applications.
Key facts
- Website
- cutiss.swiss
- Headquarters
- Zurich, Switzerland
- Founded
- 2014
- Total funding
- $135M (Series C)
- Valuation
- Private
- Business model
- B2B
- Tags
- MedTechHealthTechBiotechRegenerative MedicineTissue Engineering
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 10 Sept 2025 | Series C | $63M | Swiss Entrepreneurs Fund, Giammaria Giuliani |
| 29 Mar 2022 | Undisclosed round | $50M | - |
| 1 Mar 2021 | Undisclosed round | $10M | Giammaria Giuliani Foundation |
| 1 Jan 2019 | Undisclosed round | $3M | - |
| 1 Sept 2017 | Undisclosed round | $8M | Giammaria Giuliani Foundation |
| 1 Jan 2016 | Undisclosed round | $2M | - |
Tech stack
Detected on cutiss.swiss, last scanned 3 Sept 2026. Run your own scan
- Email provider
- Microsoft 365
Frequently asked
How much funding has CUTISS raised?
CUTISS has raised a total of $135M in funding. The most recent round on record is Series C.